Preliminary Efficacy and Safety Data from the Phase 2 Trial of Riliprubart (SAR445088), a Humanized Monoclonal Antibody Targeting Complement C1s, in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (S15.008) | Synapse
April 9, 2024
Preliminary Efficacy and Safety Data from the Phase 2 Trial of Riliprubart (SAR445088), a Humanized Monoclonal Antibody Targeting Complement C1s, in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (S15.008)
Key Points
Key points are not available for this paper at this time.
Abstract
Report preliminary efficacy and safety results for riliprubart, a novel complement C1s-inhibitor, in people with CIDP.